On October 20, 2025, Escugen presented the latest clinical data of ESG401 (a Trop2 ADC) as first-line treatment for metastatic triple-negative breast cancer in a poster at the ESMO 2025 Congress.

Shanghai, China - September 8, 2025. Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") and Huahui Health (Beijing) Biotechnology Co., Ltd. ("Huahui Health") announced today that they have entered into an exclusive global cooperation and development agreement for a novel, undisclosed tumor target. The partnership aims to jointly develop a potential "First-in-Class" antibody-drug conjugate (ADC) candidate.